$MYGN
MYRIAD GENETICS INC Stock $mygn

$mygn Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000089992323000035 Filed on May 04, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$183.5M	$181.2M
YoY Change	2.34%	9.88%
Cost Of Revenue	$57.80M	$59.20M
YoY Change	16.3%	23.33%
Gross Profit	$125.7M	$122.0M
YoY Change	-3.01%	4.36%
Gross Profit Margin	68.5%	67.33%
Selling, General & Admin	$140.7M	$151.7M
YoY Change	10.7%	37.16%
% of Gross Profit	111.93%	124.34%
Research & Development	$21.20M	$22.50M
YoY Change	4.43%	6.13%
% of Gross Profit	16.87%	18.44%
Depreciation & Amortization	$13.30M	$8.700M
YoY Change	375.0%	210.71%
% of Gross Profit	10.58%	7.13%
Operating Expenses	$161.9M	$174.2M
YoY Change	9.84%	32.17%
Operating Profit	-$36.20M	-$52.20M
YoY Change	103.37%	103.91%
Interest Expense	$0.00	$500.0K
YoY Change	-100.0%	-44.44%
% of Operating Profit
Other Income/Expense, Net	-$2.400M	-$400.0K
YoY Change	2300.0%	-50.0%
Pretax Income	-$116.1M	-$52.60M
YoY Change	548.6%	99.24%
Income Tax	$0.00	$2.100M
% Of Pretax Income
Net Earnings	-$116.1M	-$54.70M
YoY Change	723.4%	166.83%
Net Earnings / Revenue	-63.27%	-30.19%
Basic Earnings Per Share	-$1.42	-$0.67
Diluted Earnings Per Share	-$1.42	-$0.67
COMMON SHARES
Basic Shares Outstanding	81.56M shares	81.22M shares
Diluted Shares Outstanding	81.70M shares	81.30M shares

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$121.6M	$78.70M
YoY Change	-40.71%	-70.68%
Cash & Equivalents	$600.0K	$53.60M
Short-Term Investments	$18.80M	$25.10M
Other Short-Term Assets	$38.50M	$42.00M
YoY Change	4.62%	0.72%
Inventory	$22.50M	$21.80M
Prepaid Expenses
Receivables	$111.7M	$119.1M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$294.3M	$261.6M
YoY Change	-19.83%	-38.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$218.6M	$96.30M
YoY Change	314.02%	110.72%
Goodwill	$287.2M	$287.1M
YoY Change	20.77%	20.23%
Intangibles	$358.8M	$369.4M
YoY Change	-6.15%	-6.15%
Long-Term Investments	$6.200M	$30.40M
YoY Change	-92.1%	-57.06%
Other Assets	$22.10M	$17.50M
YoY Change	151.14%	113.41%
Total Long-Term Assets	$892.9M	$907.7M
YoY Change	5.91%	9.63%
TOTAL ASSETS
Total Short-Term Assets	$294.3M	$261.6M
Total Long-Term Assets	$892.9M	$907.7M
Total Assets	$1.187B	$1.169B
YoY Change	-1.9%	-6.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$39.80M	$36.50M
YoY Change	83.41%	34.69%
Accrued Expenses	$159.7M	$91.70M
YoY Change	89.22%	-26.52%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$221.1M	$143.3M
YoY Change	84.71%	-13.67%
LONG-TERM LIABILITIES
Long-Term Debt	$38.40M	$0.00
YoY Change
Other Long-Term Liabilities	$188.8M	$11.50M
YoY Change	3917.02%	134.69%
Total Long-Term Liabilities	$227.2M	$11.50M
YoY Change	4734.04%	134.69%
TOTAL LIABILITIES
Total Short-Term Liabilities	$221.1M	$143.3M
Total Long-Term Liabilities	$227.2M	$11.50M
Total Liabilities	$452.0M	$334.1M
YoY Change	71.99%	9.43%
SHAREHOLDERS EQUITY
Retained Earnings	-$537.0M	-$420.9M
YoY Change	85.94%	53.22%
Common Stock	$1.278B	$1.264B
YoY Change	2.61%	2.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$735.2M	$835.2M
YoY Change
Total Liabilities & Shareholders Equity	$1.187B	$1.169B
YoY Change	-1.9%	-6.86%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	-$116.1M	-$54.70M
YoY Change	723.4%	166.83%
Depreciation, Depletion And Amortization	$13.30M	$8.700M
YoY Change	375.0%	210.71%
Cash From Operating Activities	-$900.0K	-$33.20M
YoY Change	-98.21%	-28.6%
INVESTING ACTIVITIES
Capital Expenditures	$18.80M	$23.50M
YoY Change	-380.6%	-473.02%
Acquisitions
YoY Change
Other Investing Activities	$30.60M	$58.10M
YoY Change	-677.36%	-266.0%
Cash From Investing Activities	$11.80M	$34.60M
YoY Change	-198.33%	-183.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	38.40M	-$4.900M
YoY Change	1436.0%	2.08%
NET CHANGE
Cash From Operating Activities	-900.0K	-$33.20M
Cash From Investing Activities	11.80M	$34.60M
Cash From Financing Activities	38.40M	-$4.900M
Net Change In Cash	49.30M	-$3.300M
YoY Change	-182.44%	-96.46%
FREE CASH FLOW
Cash From Operating Activities	-$900.0K	-$33.20M
Capital Expenditures	$18.80M	$23.50M
Free Cash Flow	-$19.70M	-$56.70M
YoY Change	-54.82%	41.04%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000899923
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	84108
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://www.myriad.com/20230331#TestingMember
CY2022Q1	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://www.myriad.com/20230331#TestingMember
CY2023Q1	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://www.myriad.com/20230331#TestingMember
CY2022Q1	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://www.myriad.com/20230331#TestingMember
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	0-26642
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	MYRIAD GENETICS, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	320 Wakara Way
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Salt Lake City
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	UT
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-0494517
CY2023Q1	dei	City Area Code CityAreaCode	801
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	584-3600
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value
CY2023Q1	dei	Trading Symbol TradingSymbol	MYGN
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	81555161	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	53600000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56900000	usd
CY2023Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	25100000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	58000000.0	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	119100000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	101600000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	21800000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	20100000	usd
CY2023Q1	us-gaap	Prepaid Taxes PrepaidTaxes	17600000	usd
CY2022Q4	us-gaap	Prepaid Taxes PrepaidTaxes	17600000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	24400000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	20400000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	261600000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	274600000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	107000000.0	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	103900000	usd
CY2023Q1	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	30400000	usd
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	54800000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	96300000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	83400000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	369400000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	379700000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	287100000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	286800000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	17500000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	15500000	usd
CY2023Q1	us-gaap	Assets Assets	1169300000	usd
CY2022Q4	us-gaap	Assets Assets	1198700000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	36500000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	28800000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	91700000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	94300000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	15100000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	14100000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	143300000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	137200000	usd
CY2023Q1	mygn	Unrecognized Tax Benefits Net UnrecognizedTaxBenefitsNet	28700000	usd
CY2022Q4	mygn	Unrecognized Tax Benefits Net UnrecognizedTaxBenefitsNet	26800000	usd
CY2023Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4100000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	3500000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	146500000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	130900000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	11500000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	14500000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	334100000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	312900000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	81500000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	81200000	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	800000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	800000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1262700000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1260100000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-7400000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-8900000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-420900000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-366200000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	835200000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	885800000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1169300000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1198700000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	181200000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	164900000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	59200000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	48000000.0	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22500000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21200000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	151700000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	110600000	usd
CY2023Q1	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2022Q1	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	10700000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	233400000	usd
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	190500000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-52200000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-25600000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	700000	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	100000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	500000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	900000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-600000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-400000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-800000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-52600000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-26400000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2100000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5900000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-54700000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-20500000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.67
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.67
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	81300000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	81300000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	80100000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	80100000	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-54700000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-20500000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1200000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1300000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	300000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1200000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-53200000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23000000.0	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	967800000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-4800000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10100000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-20500000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2500000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	950100000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	885800000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-4900000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7500000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-54700000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1500000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	835200000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-54700000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-20500000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	19400000	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	13000000.0	usd
CY2023Q1	mygn	Non Cash Interest Expense NonCashInterestExpense	300000	usd
CY2022Q1	mygn	Non Cash Interest Expense NonCashInterestExpense	200000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2900000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	3100000	usd
CY2023Q1	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	-13200000	usd
CY2022Q1	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	0	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7500000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	10100000	usd
CY2023Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	100000	usd
CY2022Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-5900000	usd
CY2023Q1	mygn	Increase Decrease In Unrecognized Tax Benefits IncreaseDecreaseInUnrecognizedTaxBenefits	1900000	usd
CY2022Q1	mygn	Increase Decrease In Unrecognized Tax Benefits IncreaseDecreaseInUnrecognizedTaxBenefits	200000	usd
CY2023Q1	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	-500000	usd
CY2022Q1	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	0	usd
CY2023Q1	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2022Q1	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	10700000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	4000000.0	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	3000000.0	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	17500000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10500000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1700000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	200000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Taxes IncreaseDecreaseInPrepaidTaxes	0	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Taxes IncreaseDecreaseInPrepaidTaxes	400000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	2300000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	300000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	7600000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3200000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-6500000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-35300000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	100000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-4500000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-33200000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-46500000	usd
CY2023Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	23500000	usd
CY2022Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	6300000	usd
CY2023Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	usd
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	52100000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	58100000	usd
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	17100000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	34600000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-41300000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	0	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	300000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	4900000	usd
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	5100000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-4900000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-4800000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	200000	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-600000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3300000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-93200000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	66400000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	258800000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	63100000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	165600000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	181200000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	164900000	usd
CY2022Q1	us-gaap	Contract With Customer Asset Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	12400000	usd
CY2023Q1	us-gaap	Capitalized Contract Cost Gross CapitalizedContractCostGross	0	usd
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Concentration of Credit RiskFinancial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Substantially all of the Company’s accounts receivable are with companies in the healthcare industry, U.S. and state governmental agencies, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related healthcare programs are funded by the U.S. and state governments.
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	53600000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	53600000	usd
CY2023Q1	mygn	Investments And Cash Amortized Cost InvestmentsAndCashAmortizedCost	110600000	usd
CY2023Q1	mygn	Investments And Cash Accumulated Gross Unrealized Gain Before Tax InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2023Q1	mygn	Investments And Cash Accumulated Gross Unrealized Loss Before Tax InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax	1500000	usd
CY2023Q1	us-gaap	Investments And Cash InvestmentsAndCash	109100000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56900000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	56900000	usd
CY2022Q4	mygn	Investments And Cash Amortized Cost InvestmentsAndCashAmortizedCost	172400000	usd
CY2022Q4	mygn	Investments And Cash Accumulated Gross Unrealized Gain Before Tax InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	mygn	Investments And Cash Accumulated Gross Unrealized Loss Before Tax InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax	2700000	usd
CY2022Q4	us-gaap	Investments And Cash InvestmentsAndCash	169700000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	25400000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	25100000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	31600000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	30400000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost	0	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	0	usd
CY2023Q1	mygn	Investments And Cash Amortized Cost InvestmentsAndCashAmortizedCost	110600000	usd
CY2023Q1	us-gaap	Investments And Cash InvestmentsAndCash	109100000	usd
CY2023Q1	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	50400000	usd
CY2022Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	109300000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	208500000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	192600000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	112200000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	109200000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	96300000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	83400000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	8700000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	2800000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	286800000	usd
CY2023Q1	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	300000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	287100000	usd
CY2023Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	633300000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	263900000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	369400000	usd
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	632700000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	253000000.0	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	379700000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	10700000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	10200000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	39100000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	41200000	usd
CY2023Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	4700000	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	4800000	usd
CY2023Q1	mygn	Refunds Payable And Reserve Current RefundsPayableAndReserveCurrent	18500000	usd
CY2022Q4	mygn	Refunds Payable And Reserve Current RefundsPayableAndReserveCurrent	19300000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	3000000.0	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	0	usd
CY2023Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	5000000.0	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	4800000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	21400000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	24200000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	91700000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	94300000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	0	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	0	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3800000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	6800000	usd
CY2023Q1	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	7700000	usd
CY2022Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	7700000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	11500000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	14500000	usd
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	0	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	81500000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	81500000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	81200000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	81200000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	80000000.0	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	80000000.0	shares
CY2023Q1	mygn	Stock Issued During Period Shares Share Based Payment Arrangement And Employee Stock Purchase Plans StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans	300000	shares
CY2022Q1	mygn	Stock Issued During Period Shares Share Based Payment Arrangement And Employee Stock Purchase Plans StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans	300000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	81500000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	81500000	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	80300000	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	80300000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	81300000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	80100000	shares
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2022Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	81300000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	80100000	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5600000	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5500000	shares
CY2016Q2	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	200000000	usd
CY2023Q1	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	110700000	usd
CY2023Q1	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	0	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	700000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.38
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	0	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	700000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.38
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	400000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	13.38
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	900000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7500000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	10100000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2100000	usd
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.040
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5900000	usd
CY2022Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.223
CY2023Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	300000	usd
CY2022Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	300000	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	6000000.0	usd
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023Q1	mygn	Operating Lease Liability Established OperatingLeaseLiabilityEstablished	6000000.0	usd
CY2022Q1	mygn	Operating Lease Liability Established OperatingLeaseLiabilityEstablished	800000	usd
CY2023Q1	mygn	Tenant Improvement Allowance Not Yet Received TenantImprovementAllowanceNotYetReceived	2700000	usd
CY2022Q1	mygn	Tenant Improvement Allowance Not Yet Received TenantImprovementAllowanceNotYetReceived	0	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	8000000.0	usd
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	900000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	53600000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	164200000	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	9500000	usd
CY2022Q1	us-gaap	Restricted Cash RestrictedCash	1400000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	63100000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	165600000	usd
CY2022Q1	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	8600000	usd
CY2022Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	10700000	usd

Files In Submission

Name	View Source	Status
0000899923-23-000035-index-headers.html	Edgar Link	pending
0000899923-23-000035-index.html	Edgar Link	pending
0000899923-23-000035.txt	Edgar Link	pending
0000899923-23-000035-xbrl.zip	Edgar Link	pending
exhibit311-certificationof.htm	Edgar Link	pending
exhibit312-certificationof.htm	Edgar Link	pending
exhibit321-certificationpu.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mygn-20230331.htm	Edgar Link	pending
mygn-20230331.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
mygn-20230331_cal.xml	Edgar Link	unprocessable
mygn-20230331_def.xml	Edgar Link	unprocessable
mygn-20230331_lab.xml	Edgar Link	unprocessable
mygn-20230331_pre.xml	Edgar Link	unprocessable
mygn-20230331_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
restrictedstockunitagreeme.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MYGN
MYRIAD GENETICS INC Stock $mygn

2023 Q2 Form 10-Q Financial Statement

#000089992323000035 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MYGN MYRIAD GENETICS INC Stock $mygn

2023 Q2 Form 10-Q Financial Statement

#000089992323000035 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MYGN
MYRIAD GENETICS INC Stock $mygn